| Not Yet Recruiting | Using MSCs for Chronic Active Antibody Mediated Rejection NCT07005687 | Shahid Beheshti University of Medical Sciences | N/A |
| Not Yet Recruiting | AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function NCT05432765 | University of Florida | N/A |
| Not Yet Recruiting | Treatment of Antibody-Mediated Rejection (ABMR) With CarBel NCT06918990 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD- NCT07415876 | Virginia Commonwealth University | — |
| Recruiting | A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Tra NCT07412470 | Sanofi | Phase 2 / Phase 3 |
| Not Yet Recruiting | Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Don NCT06291103 | University Hospital, Rouen | Phase 2 / Phase 3 |
| Not Yet Recruiting | PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients) NCT07231328 | Transplant Genomics, Inc. | — |
| Recruiting | Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring NCT07060716 | Insight Molecular Diagnostics | — |
| Not Yet Recruiting | GEnomic Medicine in Kidney Transplantation Study NCT06365411 | Western Sydney Local Health District | — |
| Recruiting | CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk NCT07053462 | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients NCT06852625 | Fundacion Clinic per a la Recerca Biomédica | Phase 1 |
| Active Not Recruiting | PROACT Pilot Trial NCT06564649 | University of British Columbia | — |
| Recruiting | Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab NCT07006532 | Shahid Beheshti University of Medical Sciences | N/A |
| Withdrawn | Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transpla NCT03605654 | Medeor Therapeutics, Inc. | Phase 2 / Phase 3 |
| Withdrawn | Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Trans NCT03606746 | Medeor Therapeutics, Inc. | Phase 2 |
| Recruiting | Platelet Aggregation in the Diagnosis of Acute Graft Rejection NCT07275541 | University Hospital, Martin | — |
| Enrolling By Invitation | PRObiotics for KIdney Transplantation NCT06825117 | University Hospital, Udine, Italy | N/A |
| Suspended | Utilising Volumetric Absorptive Microsampling (VAMS) Technology to Monitor Tacrolimus and Creatinine NCT06445205 | Lancashire Teaching Hospitals NHS Foundation Trust | — |
| Recruiting | Multi Center Observation of Sentinel Skin Graft for Detecting Acute Rejection After Renal Transplantation NCT05600634 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Reduced-dose Alemtuzumab for Kidney Transplant Rejection NCT06100965 | Erasmus Medical Center | — |
| Enrolling By Invitation | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients NCT06126380 | Eledon Pharmaceuticals | Phase 2 |
| Recruiting | Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Reci NCT06025240 | Liverpool University Hospitals NHS Foundation Trust | — |
| Completed | SRDK0921_ Analytical Performance Study NCT05747274 | BioMAdvanced Diagnostics | — |
| Terminated | Improving KIdney Transplantation with Cellular Therapy Study NCT06243289 | Western Sydney Local Health District | — |
| Completed | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation NCT05983770 | Eledon Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) NCT05987527 | Sangamo Therapeutics | — |
| Active Not Recruiting | Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospect NCT05836636 | Singapore General Hospital | — |
| Unknown | Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients NCT05872568 | Zhishui Chen | Phase 4 |
| Active Not Recruiting | The smartNTx Trial: A Prospective, Randomized Controlled Trial (RCT) to Investigate Additional Interventional NCT05897047 | University of Erlangen-Nürnberg Medical School | N/A |
| Unknown | Immune Response in Desensitized Patients NCT05785936 | University Hospital, Grenoble | — |
| Not Yet Recruiting | BAFF/APRIL in Kidney Transplant Rejection Risk Assessment NCT05779124 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients NCT05727709 | Tongji Hospital | — |
| Completed | Impact of Microvascular Inflammation on Kidney Allograft Outcome NCT06496269 | Paris Translational Research Center for Organ Transplantation | — |
| Unknown | ddcfDNA in Kidney Transplant Recipients NCT06013358 | Seoul National University Hospital | — |
| Withdrawn | Immunosuppression Reduction in Failed Allograft Guided by cfDNA NCT04560582 | University of Minnesota | — |
| Not Yet Recruiting | CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients NCT05482100 | Transplant Genomics, Inc. | — |
| Unknown | Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Re NCT04414735 | Fundacion Clinic per a la Recerca Biomédica | N/A |
| Enrolling By Invitation | Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation NCT05285878 | The Methodist Hospital Research Institute | Phase 2 |
| Active Not Recruiting | Clinical Impact of the IBox As an Early Intervention TooL NCT05112315 | Predict4Health | N/A |
| Unknown | Tacrolimus Exposure in Kidney Transplantation NCT06348446 | Seoul National University Hospital | — |
| Unknown | TruGraf and TRAC In Pediatrics Study NCT05335538 | Transplant Genomics, Inc. | — |
| Terminated | Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR NCT04773392 | University of Southern California | Phase 4 |
| Recruiting | Impact of the Microbiota on the Likelihood of Renal Graft Rejection NCT04736381 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Unknown | Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test NCT04670926 | Transplant Genomics, Inc. | N/A |
| Completed | Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection NCT04897438 | Charite University, Berlin, Germany | N/A |
| Unknown | Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) NCT04849533 | University of Cincinnati | Phase 4 |
| Withdrawn | Spleen Transplant in Solid Organ Transplantation NCT04827186 | University of Illinois at Chicago | N/A |
| Active Not Recruiting | Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection NCT04727788 | Verici Dx | — |
| Active Not Recruiting | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant R NCT04817774 | Sangamo Therapeutics | Phase 1 / Phase 2 |
| Completed | Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based NCT04825262 | Singapore General Hospital | N/A |
| Terminated | An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR NCT04711850 | Hansa Biopharma AB | — |
| Recruiting | Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Pa NCT04702022 | University of Liege | N/A |
| Completed | Transition of Renal Patients Using AlloSure Into Community Kidney Care NCT04601155 | CareDx | — |
| Terminated | Personalization of Immunosuppressive Treatment for Organ Transplant Recipients NCT05747053 | George Washington University | — |
| Unknown | TruGraf® Long-term Clinical Outcomes Study NCT04491552 | Transplant Genomics, Inc. | — |
| Terminated | Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care NCT04267016 | Transplant Genomics, Inc. | — |
| Unknown | The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma NCT04657562 | National Science Centre, Poland | — |
| Unknown | Molecular Biomarkers in Renal Transplantation Via TruGraf® Test NCT04398498 | Transplant Genomics, Inc. | — |
| Terminated | TruGraf® Testing in High-Risk Kidney Transplant Recipients NCT04266613 | Transplant Genomics, Inc. | — |
| Completed | Desensitization in Kidney Allograft Using Daratumumab NCT04204980 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Active Not Recruiting | Microbiome and Immunosuppression: The Mission Study NCT04953715 | The University of Texas Medical Branch, Galveston | — |
| Completed | Immune Monitoring to Facilitate Belatacept Monotherapy NCT04177095 | Massachusetts General Hospital | Phase 4 |
| Unknown | Protocol Biopsies in High-risk Renal Transplant Recipients NCT04154267 | Hospital de Clinicas de Porto Alegre | N/A |
| Completed | Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients NCT04130685 | Rush University Medical Center | — |
| Completed | Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Ant NCT04225988 | Cedars-Sinai Medical Center | Phase 4 |
| Recruiting | Trifecta-Kidney cfDNA-MMDx Study NCT04239703 | University of Alberta | — |
| Terminated | Immunosuppressant Medication Dosed Daily After Kidney Transplant NCT04156204 | University of Colorado, Denver | EARLY_Phase 1 |
| Active Not Recruiting | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) NCT04091984 | Natera, Inc. | — |
| Completed | Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection NCT04367610 | Istanbul University | — |
| Terminated | Transplant Antibody-Mediated Rejection: Guiding Effective Treatments NCT03994783 | Imperial College London | Phase 3 |
| Completed | Cf-DNA Assay During Treatment of Acute Rejection NCT04019353 | University of Minnesota | — |
| Completed | An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Pa NCT03897205 | Hansa Biopharma AB | Phase 2 |
| Active Not Recruiting | Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated R NCT03859388 | Cedars-Sinai Medical Center | — |
| Unknown | Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance NCT04566055 | CareDx | — |
| Completed | Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN NCT03652402 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients NCT03714113 | Medical University of Warsaw | N/A |
| Unknown | Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Tr NCT03789006 | University of Khartoum | Phase 4 |
| Completed | Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants NCT03363945 | Medeor Therapeutics, Inc. | Phase 3 |
| Completed | Expressive Writing in Kidney Transplant Patients NCT04143178 | University of Roma La Sapienza | N/A |
| Completed | Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant NCT03380377 | Stanley Jordan, MD | Phase 1 / Phase 2 |
| Unknown | Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry NCT03326076 | CareDx | — |
| Terminated | Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients NCT03380936 | University of Colorado, Denver | EARLY_Phase 1 |
| Unknown | IL2 Imaging in Renal Transplantation NCT03304223 | University Medical Center Groningen | N/A |
| Unknown | Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients NCT03488771 | Clinical Hospital Merkur | — |
| Completed | Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients NCT03006419 | Coordinación de Investigación en Salud, Mexico | Phase 4 |
| Completed | The TOGETHER Project - Kidney RNA-seq Validation NCT03874299 | Mayo Clinic | — |
| Terminated | Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation NCT02974686 | Washington University School of Medicine | Phase 4 |
| Completed | The TOGETHER Project - Kidney NCT03873623 | Mayo Clinic | — |
| Unknown | Development and Validation of a Comprehensive Classification Automation System for Kidney Allograft Biopsies NCT05306795 | Paris Translational Research Center for Organ Transplantation | — |
| Completed | The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant NCT03965559 | Chiang Mai University | — |
| Terminated | Mesenchymal Stromal Cells in Kidney Transplant Recipients NCT02012153 | Mario Negri Institute for Pharmacological Research | Phase 1 |
| Completed | Pediatric Induction Therapy in Kidney Transplantation NCT06087003 | Gang Chen | — |
| Recruiting | Australian Genomics Of Chronic Allograft Dysfunction Study NCT06314230 | Western Sydney Local Health District | — |
| Active Not Recruiting | Observational Cohort Study Renal Transplantation University Hospitals Leuven NCT06505200 | Universitaire Ziekenhuizen KU Leuven | — |